- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Clozapine, but not olanzapine or quetiapine, linked with higher perimyocarditis and HF risk
A recent population-based study published in Psychiatry Research by Eric Clapham and colleagues has studied concerns about associations between the use of clozapine, an antipsychotic medication, and cardiac adverse events. The study's findings highlight a significantly higher risk of perimyocarditis and heart failure among individuals using clozapine, raising important questions about the safety profile of this medication.
Researchers delved into Swedish national registers to identify patients aged 16 to 75 years who had received antipsychotic medications between 2005 and 2018. The study assessed the risk of perimyocarditis (pericarditis and/or myocarditis) within two months of starting the medication and heart failure (including cardiomyopathy) within three years. The analyses
utilized Cox regressions with time-varying exposure to estimate hazard rates and their corresponding 95% confidence intervals.
● The study cohort included a total of 201,045 individuals.
● Results unveiled a striking threefold increased risk of perimyocarditis during clozapine treatment compared to no antipsychotic treatment (HR 3.4, CI 1.6–7.3).
● While the absolute rate remained relatively low, the association raised concerns.
● The long-term risk of heart failure was also elevated among clozapine users (HR 1.3, CI 1.1–1.7).
● Treatment with olanzapine or quetiapine, both chemically related to clozapine, did not exhibit the same associations with increased risk of cardiac adverse events.
The findings from this study underscore the importance of monitoring individuals undergoing clozapine treatment for potential cardiac adverse events, particularly perimyocarditis and heart failure. These associations suggest the need for vigilant evaluation and management of patients on clozapine therapy, especially within the first few months of treatment. However, it's crucial to note that while the relative risks were heightened, the absolute rates of these events remained comparably low.
This population-based study illuminates the connection between clozapine, a widely used antipsychotic, and an elevated risk of cardiac adverse events. The identified associations with perimyocarditis and heart failure underscore the need for healthcare providers to be
vigilant when prescribing clozapine, particularly considering its unique risks. As researchers continue to explore these associations, medical professionals will gain valuable insights to ensure patient safety and effective treatment strategies.
Reference:
Clapham, E., Reutfors, J., Linder, M., Brandt, L., Sundström, J., & Bodén, R. (2023). The association between exposure to clozapine, olanzapine, and quetiapine and the outcomes perimyocarditis and heart failure: A population-based cohort study. Psychiatry Research, 326(115336), 115336. https://doi.org/10.1016/j.psychres.2023.115336
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751